Jon M. Wigginton
Yale New Haven Hospital
3 papers in the Anchorcite directory, published between 2012 and 2013, cited 25,134 times in total.
Research topics
- Cancer Immunotherapy and Biomarkers · 3 papers
- Immunotherapy and Immune Responses · 3 papers
- T-cell and B-cell Immunology · 2 papers
- Cutaneous Melanoma Detection and Management · 1 paper
Frequent co-authors
- Alan J. Korman · 3 papers
- Ashok Kumar Gupta · 3 papers
- Suzanne Louise Topalian · 2 papers
- Julie Renee Brahmer · 2 papers
- Charles G. Drake · 2 papers
- Drew M. Pardoll · 2 papers
- Mario Sznol · 2 papers
- Frank Stephen Hodi · 1 paper
Papers
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in CancerNew England Journal of Medicine · 2012 · 12,793 citations
BACKGROUND: Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1. METHODS: We enrolled patients with advanced melanoma,…
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced CancerNew England Journal of Medicine · 2012 · 8,054 citations
BACKGROUND: Programmed death 1 (PD-1) protein, a T-cell coinhibitory receptor, and one of its ligands, PD-L1, play a pivotal role in the ability of tumor cells to evade the host's immune system. Blockade of interactions between PD-1 and PD-L1 enhances…
- Nivolumab plus Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2013 · 4,287 citations
BACKGROUND: In patients with melanoma, ipilimumab (an antibody against cytotoxic T-lymphocyte-associated antigen 4 [CTLA-4]) prolongs overall survival, and nivolumab (an antibody against the programmed death 1 [PD-1] receptor) produced durable tumor regression in a phase 1 trial. On the basis…
Metadata from OpenAlex (CC0).